Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (109)	2/3/2005 9:40:12 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 253

>> ProMune triggers TLR9 to direct the immune system to attack malignant cells. Through TLR9, ProMune activates directly and selectively plasmacytoid dendritic cells and B cells, which utilize the tumor's own antigens, reversing immune tolerance to malignant cells and driving specific and sustained production of both antigen specific cytotoxic T cells (CTLs) and antibodies. << Translating to humans, total and unadulterated BS. But I'm very interested in TLR agonists, for reasons apart from malignancy.